论文部分内容阅读
作为目前肿瘤治疗主要手段之一的化疗应用广泛,对其疗效的评价依据基于影像学肿瘤缩小而设计的RECIST标准,一般在2～4个周期化疗后进行评估。姑且不论在影像学图像如CT片上进行测量,容易产生对可评价病灶数毫米级的测量出入,以及存在于测量者与测量者之间的差异;这样的以“周期”为测量单位跨度占据患者28～84d的时间,有的患者可能在第1周期就耐药,有的患者转移可能已经发生,有的患者可能错过最佳治疗时机等。由于有诸多的“可能”会发生,因此,需要更敏感、即时且更早期的评价指标以监测化疗患者的疗效。
As one of the main means of cancer treatment, chemotherapy is widely used. The evaluation of its efficacy is based on the RECIST standard designed on the basis of imaging tumor shrinkage, and is generally evaluated after 2 to 4 cycles of chemotherapy. Regardless of the imaging images such as CT measurements on the film, easy to produce measurable lesions on the millimeter-level measurement of access, and there is the difference between the surveyor and the surveyor; such “cycle” as the unit of measurement span Occupy the patient’s 28 ~ 84d time, some patients may be resistant in the first cycle, some patients may have occurred in the transfer, and some patients may miss the best timing of treatment. As there are many “possible” occurrences, more sensitive, immediate and earlier measures of evaluation are needed to monitor the efficacy of chemotherapy in patients.